Lanthanide Complex Prodrugs for Targeted Cancer Theranostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer prodrugs face challenges in achieving optimal pharmacokinetics with minimal adverse side effects due to non-specific distribution and difficulty in tracing their activities in vivo, and there is a need for improved therapeutic and diagnostic properties for targeted cancer therapy.
Innovation Solution
Development of biocompatible lanthanide complexes that selectively target cancer cells, allowing for visualization and controlled release of cytotoxic d-transition metal complexes like cisplatin, utilizing responsive signaling for imaging and therapy, with specific peptides for cancer-specific receptors such as integrin αvβ3.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer prodrugs are used, then therapeutic effect is achieved, but non-specific distribution causes adverse side effects
Solution Approach 1:
The prodrug is segmented into distinct functional modules: a tumor-targeting ligand (for specific receptor binding), a cleavable linker (for controlled drug release), and a cytotoxic payload (for therapeutic effect). This segmentation allows the drug to remain inactive during circulation and only activate at the target site, reducing off-target toxicity while maintaining therapeutic efficacy.
Solution Approach 2:
The prodrug design implements local quality by concentrating the cytotoxic activity specifically at the tumor site through receptor-mediated targeting. The active drug is released only in the local tumor environment where the targeting ligand binds to overexpressed receptors, ensuring that the harmful therapeutic effect is localized to cancer cells while sparing healthy tissues.
2Productivity
If conventional prodrugs are used, then drug delivery is optimized, but tracing activities in-vitro or in-vivo is difficult
Solution Approach 1:
The prodrug molecule is designed with multi-functionality, simultaneously serving as a delivery vehicle, a targeting agent, and a diagnostic probe. The incorporation of fluorescent or radiolabeled moieties enables the same molecule to be tracked in real-time during circulation and at the target site, while also delivering the therapeutic payload, thus eliminating the need for separate diagnostic agents.
Solution Approach 2:
The prodrug incorporates fluorophores or chromophores that exhibit detectable optical properties (fluorescence emission or color changes) that allow visual tracking of the drug's distribution and accumulation at the tumor site. This optical signaling capability provides real-time feedback on drug delivery efficiency and target engagement without interfering with the therapeutic function.
3Reliability
If tumor-specific targeting is implemented, then therapeutic efficacy is enhanced, but dark cytotoxicity increases
Solution Approach 1:
The prodrug is designed to accumulate at the tumor site through active targeting before activation occurs. The targeting ligand enables the prodrug to bind to tumor cell receptors and internalize in advance, concentrating the inactive prodrug formulation at the target site before any cytotoxic activation takes place, thereby minimizing exposure of healthy cells to the cytotoxic agent.
Solution Approach 2:
A cleavable linker or spacer acts as an intermediary between the targeting ligand and the cytotoxic payload. This intermediary protects the cytotoxic drug from premature activation during circulation and targeting processes, and is designed to be cleaved only under specific tumor microenvironment conditions (such as low pH, specific enzymes, or redox conditions), thereby controlling the timing and location of cytotoxicity activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables selective differentiation and visualization of cancer cells, reduces dark cytotoxicity, and allows for real-time monitoring of drug delivery and biodistribution, enhancing therapeutic efficacy while minimizing side effects.
Implementation Method 1
whose delivery can be visualized using a non-toxic excitation wavelength
Implementation Method 2
release of the cytotoxic d-transition metal complexes (such as cisplatin, ruthenium polypyridine complexes, etc) is triggered selectively upon reaching the overexpressed cancer specific membrane receptor
Implementation Method 3
magnetic resonance and fluorescence in-vitro or in-vivo studies
Implementation Method 4
magnetic resonance and fluorescence in-vitro or in-vivo studies
Data Source
AI summary
The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin αvβ3.